Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More
Rapid spending isn’t always a sign of progress.
Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 7.1% in the afternoon session after the company trimmed the upper end of its 2025 revenue forecast, citing a delay in vaccine shipments. The company pointed to a delay in vaccine deliveries to the United Kingdom, which it pushed into the first quarter of 2026. This news overshadowed second-quarter results that beat Wall Street expectations. For the quarter, Moderna's revenue dropped about 41% from the previous year to $142 million, driven by lower sales of its COVID-19 vaccine. Despite the revenue decline, the company successfully narrowed its net loss as its cost-cutting measures took effect. Adding to the pressure, Moderna also announced plans to reduce its workforce by 10% and confirmed a delay in the U.S. approval for its combined COVID-flu vaccine until 2026.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.
Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results.
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
The vaccine maker lowered its full-year revenue guidance to a range of $1.5 billion to $2.2 billion, reflecting a $300 million reduction at the high end of the range.
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 41.1% year on year to $142 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 10.6% below analysts’ estimates. Its GAAP loss of $2.13 per share was 29.8% above analysts’ consensus estimates.
CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.
CEO Stéphane Bancel said in a note to employees on Thursday that the move is part of the company’s commitment to reduce annual operating expenses by about $1.5 billion by 2027.
